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REPLY
The question of clinical utility of measurement of plasma
brain natriuretic peptide (BNP) after an acute myocardial
infarction (AMI), raised by Drs. Rashidi and Adler, is most
pertinent and relevant. Indeed, a simple measurement of
BNP from the blood sample might have clinical importance
in estimation of candidacy for implantable cardioverter-
defibrillator (ICD) therapy. We would like to add a few
more comments to the issue of risk stratification of patients
after an AMI and of potential clinical utility of BNP
measurement.
The post hoc analysis of the Multicenter Automatic
Defibrillator Implantation Trial II (MADIT II) investiga-
tors showed that patients with a recent AMI (18 months)
did not have a mortality benefit from the ICD therapy (1).
Similar preliminary data were presented at the American
College of Cardiology meeting in March 2004 (unpub-
lished) from the Defibrillator In Acute Myocardial Infarc-
tion Trial (DINAMIT), where ICD therapy did not reduce
all-cause mortality among the patients with a recent AMI
(ejection fraction [EF] 0.35) and reduced heart rate
variability. Therefore, evaluation of the candidacy for ICD
therapy shortly after an AMI is still a challenge and an
obvious field for further research.
Our study showed that patients with a low plasma BNP
level, measured at the convalescent phase after an AMI,
have an extremely low incidence of sudden cardiac death
(SCD) (2). Our main implication is that the measurement
of BNP can be used to identify the “low-risk” patients who
may not need further risk stratification and may not benefit
from prophylactic ICD despite depressed left ventricular
function. For example, there were no SCDs among the
patients with an EF 0.35 and low BPN (23.0 pmol/l)
during the follow-up. Also, BNP did not reach statistical
significance in prediction of SCD among patients with an
EF between 0.30 and 0.40. However, elevated BNP had a
better predictive power among those with preserved left
ventricular function (EF 0.40) (relative risk 3.9; 95%
confidence interval 1.0 to 16.5; p  0.05). Patients with an
EF 0.40 also constituted the highest cumulative number
of SCD events. Prediction and prevention of SCD among
the large number of survivors of AMI who have a preserved
left ventricular function will be important in future efforts
aimed at reducing the overall burden of premature SCD.
Measurement of BNP may have clinical value in this
respect.
In conclusion, we believe measurement of BNP at the
convalescent phase after an AMI is most suitable for
excluding patients at risk for future SCD. Evaluation of the
candidacy for ICD therapy shortly after an AMI still
remains a challenge both for scientists and clinicians.
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Does Nondipping Blood Pressure
Profile Contribute to Vascular
Inflammation During Sleep Deprivation?
We read with great interest the study by Meier-Ewert et al.
(1) describing elevated high sensitivity C-reactive protein
(hs-CRP) in healthy subjects after both acute total and
partial sleep deprivation. The investigators hypothesized
that such low-grade inflammation associated with sleep loss
might contribute to the increased cardiovascular risk de-
scribed in sleep complaints.
As far as the mechanisms responsible for such increment
of circulating hs-CRP levels after sleep deprivation, the
researchers suggest a role for vascular shear stress exacer-
bated by increased blood pressure (BP) levels (1). In this
context, a trend toward an increment of systolic and
diastolic BP was observed during both total and partial sleep
deprivation. However, only changes of systolic BP across
total sleep deprivation achieved statistical significance. In
addition, circulating hs-CRP levels significantly increased,
starting with the first day of total sleep deprivation, despite
irrelevant changes of systolic and diastolic BP. Thus, sleep
deprivation-related increments of BP do not completely
explain the interesting findings by Meier-Ewert et al. (1).
In this regard, sleep disturbances strongly affect both
nighttime blood pressure levels and the nocturnal BP drop
in healthy subjects as well as in hypertensive patients (2).
The blunted nocturnal decline in BP, also known as
“nondipping profile,” has been reported to be associated
with increased vascular damage, at least in hypertensive
patients (3). In keeping with this, a nondipping profile has
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